Jacob Boydstun, DO
Psychiatry · Little Rock, ARNPI 1568805299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 24.9% of the total. Reporting peaked in 2024 at $585 and has fallen 88.6% since, to $67 in 2025.
Across 86 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$492
- Otsuka America Pharmaceutical, Inc.$323
- Alkermes, Inc.$297
- Vanda Pharmaceuticals Inc.$242
- Indivior Inc.$197
- AbbVie$192
- plus $235 from 6 others
What the payments were for
- Food & beverage$1,96399%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 14 | $492 |
| Otsuka America Pharmaceutical, Inc. | 15 | $323 |
| Alkermes, Inc. | 16 | $297 |
| Vanda Pharmaceuticals Inc. | 9 | $242 |
| Indivior Inc. | 8 | $197 |
| AbbVie(2 entities) | 11 | $192 |
| Sunovion Pharmaceuticals Inc. | 6 | $108 |
| Neurocrine Biosciences, Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$250
How this compares
$1,978 in reported general payments places this provider in the 75th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $6,707 |
| Buprenorphine Hcl | 23 | $666 |
| Duloxetine Hcl | 20 | $509 |
| Gabapentin | 29 | $286 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $241 |
| Hydroxyzine Pamoate | 11 | $182 |
| Trazodone Hcl | 31 | $126 |
| Aripiprazole | 12 | $116 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Little Rock
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Paul WylieLittle Rock$54K
- Margaret WeissLittle Rock$29K
- Duong NguyenLittle Rock$14K
- Philip MizellLittle Rock$5K
- Richard FlaniginLittle Rock$5K
- Robert FarrellLittle Rock$4K
- Pawel KuryloLittle Rock$4K
- Gintaras AukstuolisLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.